Novel Experimental Parameters to Quantify the Modulation of Absorptive and Secretory Transport of Compounds by P-Glycoprotein in Cell Culture Models of Intestinal Epithelium

Springer Science and Business Media LLC - 2003
Matthew D. Troutman1, Dhiren R. Thakker1
1Division of Drug Delivery and Disposition, School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill

Tóm tắt

Purpose. The purpose of this work was to elucidate the asymmetric effect of P-gp on modulation of absorptive and secretory transport of compounds across polarized epithelium, to develop experimental parameters to quantify P-gp-mediated modulation of absorptive and secretory transport, and to elucidate how P-gp-mediated modulation of transport is affected by passive diffusion properties, interaction of the substrate with P-gp, and P-gp expression. Methods. The permeability of a set of P-gp substrates was determined in absorptive and secretory directions in Madine-Darby Canine kidney (MDCK), Caco-2, and MDR-MDCK monolayers. The transport was also determined in the presence of GW918, a non-competitive P-gp inhibitor, to quantify the permeability without the influence of P-gp. From these two experimental permeability values in each direction, two new parameters, absorptive quotient (AQ) and the secretory quotient (SQ), were defined to express the functional activity of P-gp during absorptive and secretory transport, respectively. Western blot analysis was used to quantify P-gp expression in these monolayers and in normal human intestinal. Results. P-gp expression in Caco-2 and MDR-MDCK monolayers was comparable to that in normal intestine, and much less in MDCK cells. For all models, the substrates encompassed a wide range of apparent permeability due to passive diffusion (P PD). The parameters AQ and SQ, calculated for all compounds, assessed the attenuation in absorptive and enhancement of secretory transport, respectively, normalized to the permeability due to passive diffusion. Analysis of these parameters showed that 1) P-gp affected absorptive and secretory transport differentially and 2) compounds could be stratified into distinct groups with respect to the modulation of their absorptive and secretory transport by P-gp. Compounds could be identified whose absorptive transport was either strongly affected or poorly affected by changes in P-gp expression. For certain compounds, AQ values showed parabolic relationship with respect to passive diffusivity, and for others AQ was unaffected by changes in passive diffusivity. Conclusions. The relationship between attenuation of absorptive transport and enhancement of secretory transport of compounds by P-gp is asymmetric, and different for different sets of compounds. The relationship between attenuation of absorption by P-gp and passive diffusivity of compounds, their interaction potential with P-gp, and levels of P-gp expression is complex; however, compounds can be classified into sets based on these relationships. A classification system that describes the functional activity of P-gp with respect to modulation of absorptive and secretory transport was developed from these results.

Từ khóa


Tài liệu tham khảo

F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-7738 (1987).

J. Hunter, B. H. Hirst, and N. L. Simmons. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10:743-749 (1993).

P. F. Augustijns, T. P. Bradshaw, L. S. Gan, R. W. Hendren, and D. R. Thakker. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197:360-365 (1993).

T. Gramatte, R. Oertel, B. Terhaag, and W. Kirch. Direct demonstration of small intestinal secretion and site-dependent absorption of the #x0392-blocker talinolol in humans. Clin. Pharmacol. Ther. 59:541-549 (1996).

M. F. Hebert. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv. Drug Deliv. Rev. 27:201-214 (1997).

W. M. Kan, Y. T. Liu, C. L. Hsiao, C. Y. Shieh, J. H. Kuo, J. D. Huang, and S. F. Su. Effect of hydroxyzine on the transport of etoposide in rat small intestine. Anticancer Drugs 12:267-273 (2001).

M. Sababi, O. Borga, and U. Hultkvist-Bengtsson. The role of P-glycoprotein in limiting intestinal #x00AEional absorption of digoxin in rats. Eur. J. Pharm. Sci. 14:21-27 (2001).

H. Saitoh and B. J. Aungst. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 12:1304-1310 (1995).

H. Saitoh, M. Hatakeyama, O. Eguchi, M. Oda, and M. Takada. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J. Pharm. Sci. 87:73-75 (1998).

H. Spahn-Langguth, G. Baktir, A. Radschuweit, A. Okyar, B. Terhaag, P. Ader, A. Hanafy, and P. Langguth. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36:16-24 (1998).

A. Sparreboom, J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. van Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031-2035 (1997).

R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).

R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood, and G. R. Wilkinson. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16:408-414 (1999).

W. L. Chiou, S. M. Chung, and T. C. Wu. Commentary: Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm. Res. 17:901-903 (2000).

K. Arimori and M. Nakano. Drug exsorption from blood into the gastrointestinal tract. Pharm. Res. 15:371-376 (1998).

U. Mayer, E. Wagenaar, J. H. Beijnen, J. W. Smit, D. K. Meijer, J. van Asperen, P. Borst, and A. H. Schinkel. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br. J. Pharmacol. 119:1038-1044 (1996).

T. Gramatte and R. Oertel. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin. Pharmacol. Ther. 66:239-245 (1999).

J. van Asperen, A. H. Schinkel, J. H. Beijnen, W. J. Nooijen, P. Borst, and O. van Tellingen. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J. Natl. Cancer Inst. 88:994-999 (1996).

J. van Asperen, O. van Tellingen, and J. H. Beijnen. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab. Dispos. 28:264-267 (2000).

U. Wetterich, H. Spahn-Langguth, E. Mutschler, B. Terhaag, W. Rosch, and P. Langguth. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration-and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13:514-522 (1996).

S. Ito, C. Woodland, P. A. Harper, and G. Koren. P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model. Life Sci. 53:L25-L31 (1993).

A. Johne, J. Brockmoller, S. Bauer, A. Maurer, M. Langheinrich, and I. Roots. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin. Pharmacol. Ther. 66:338-345 (1999).

B. Greiner, M. Eichelbaum, P. Fritz, H. P. Kreichgauer, O. von Richter, J. Zundler, and H. K. Kroemer. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:147-153 (1999).

J. G. Theis, H. S. Chan, M. L. Greenberg, D. Malkin, V. Karaskov, I. Moncica, and G. Koren. and J. Doyle. Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin. Int. J. Clin. Pharmacol. Ther. 36:61-64 (1998).

M. F. Paine, L. Y. Leung, H. K. Lim, K. Liao, A. Oganesian, M. Y. Zhang, K. E. Thummel, and P. B. Watkins. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. J. Pharmacol. Exp. Ther. 301:174-186 (2002).

L. Z. Benet, S. Oie, and J. B. Schwartz. Design and Optimization of Dosage Regimens; Pharmacokinetic Data. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon and G.G. A. (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics (J. G. Hardman L. E. Limbird P. B. Molinoff R. W. Ruddonand G. G. A., eds), McGraw-Hill, New York, 1990, pp. 1707-1792.

J. W. Polli, S. A. Wring, J. E. Humphreys, L. Huang, J. B. Morgan, L. O. Webster, and C. S. Serabjit-Singh. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299:620-628 (2001).

A. H. Schinkel. Pharmacological insights from P-glycoprotein knockout mice. Int. J. Clin. Pharmacol. Ther. 36:9-13 (1998).

T. Terao, E. Hisanaga, Y. Sai, I. Tamai, and A. Tsuji. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. 48:1083-1089 (1996).

M. D. Troutman and D. R. Thakker. Rhodamine 123 Requires Carrier-Mediated Influx for Its Activity as a P-glycoprotein Substrate in Caco-2 Cells. Pharm. Res. 20:1192-1199 (2003).

M. D. Troutman and D. R. Thakker. The Efflux Ratio Cannot Assess P-glycoprotein-Mediated Attenuation of Absorptive Transport-Asymmetric Effect of P-glycoprotein on Absorptive and Secretory Transport Across Caco-2 Cell Monolayers. Pharm Res. 20:1200-1209 (2003).

P. Schmiedlin-Ren, K. E. Thummel, J. M. Fisher, M. F. Paine, K. S. Lown, and P. B. Watkins. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol. Pharmacol. 51:741-754 (1997).

U. A. Germann, M. C. Willingham, I. Pastan, and M. M. Gottesman. Expression of the human multidrug transporter in insect cells by a recombinant baculovirus. Biochemistry 29:2295-2303 (1990).

K. Lee and D. R. Thakker. Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J. Pharm. Sci. 88:680-687 (1999).

M. J. Cho, D. P. Thompson, C. T. Cramer, T. J. Vidmar, and J. F. Scieszka. The Madin Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm. Res. 6:71-77 (1989).

O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).

F. Hyafil, C. Vergely, P. Du Vignaud, and T. Grand-Perret. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:4595-4602 (1993).

F. Ingels, S. Deferme, E. Destexhe, M. Oth, G. Van den Mooter, and P. Augustijns. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int. J. Pharm. 232:183-192 (2002).

J. Gao, O. Murase, R. L. Schowen, J. Aube, and R. T. Borchardt. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm. Res. 18:171-176 (2001).

S. Doppenschmitt, H. Spahn-Langguth, C. G. Regardh, and P. Langguth. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 88:1067-1072 (1999).

N. F. Ho, P. S. Burton, R. A. Conradi, and C. L. Barsuhn. A biophysical model of passive and polarized active transport processes in Caco-2 cells: approaches to uncoupling apical and basolateral membrane events in the intact cell. J. Pharm. Sci. 84:21-27 (1995).

S. H. Jang, M. G. Wientjes, and J. L. Au. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J. Pharmacol. Exp. Ther. 298:1236-1242 (2001).

K. A. Lentz, J. W. Polli, S. A. Wring, J. E. Humphreys, and J. E. Polli. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm. Res. 17:1456-1460 (2000).

C. Martin, G. Berridge, C. F. Higgins, P. Mistry, P. Charlton, and R. Callaghan. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58:624-632 (2000).

M. Horio, K. V. Chin, S. J. Currier, S. Goldenberg, C. Williams, I. Pastan, and M. M. Gottesman. and J. Handler. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J. Biol. Chem. 264:14880-14884 (1989).

Y. Zhang and L. Z. Benet. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm. Res. 15:1520-1524 (1998).

S. Ito, C. Woodland, B. Sarkadi, G. Hockmann, S. E. Walker, and G. Koren. Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. Am. J. Physiol. 277:F84-F96 (1999).

C. J. Matheny, M. W. Lamb, K. R. Brouwer, and G. M. Pollack. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21:778-796 (2001).

W. D. Stein. Kinetics of the P-glycoprotein, the multidrug transporter. Exp. Physiol. 83:221-232 (1998).

D. R. Ferry, P. J. Malkhandi, M. A. Russell, and D. J. Kerr. Allosteric #x00AEulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem. Pharmacol. 49:1851-1861 (1995).

R. Liu and F. J. Sharom. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry 35:11865-11873 (1996).

C. Martin, G. Berridge, C. F. Higgins, and R. Callaghan. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction. Br. J. Pharmacol. 122:765-771 (1997).

C. Martin, G. Berridge, P. Mistry, C. Higgins, P. Charlton, and R. Callaghan. Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 39:11901-11906 (2000).

K. Simons and S. D. Fuller. Cell surface polarity in epithelia. Annu. Rev. Cell Biol. 1:243-288 (1985).

K. Simons and G. van Meer. Lipid sorting in epithelial cells. Biochemistry 27:6197-6202 (1988).

I. Chantret, A. Barbat, E. Dussaulx, M. G. Brattain, and A. Zweibaum. Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res. 48:1936-1942 (1988).

C. Le Grimellec, G. Friedlander, E. H. el Yandouzi, P. Zlatkine, and M. C. Giocondi. Membrane fluidity and transport properties in epithelia. Kidney Int. 42:825-836 (1992).

C. Le Grimellec, G. Friedlander, and M. C. Giocondi. Asymmetry of plasma membrane lipid order in Madin-Darby Canine Kidney cells. Am. J. Physiol. 255:F22-F32 (1988).

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả